

25. (Amended) The oligomer of {Use of oligomers according to} claim 1 wherein the oligomer is used [*in vitro* as one of the binding reagents] in an enzyme immunoassay.

26. (Amended) The oligomer of [Use of oligomers according to] claim 1 wherein the oligomer is used [*in vitro* as one of the binding reagents] in a radioimmunoassay[s].

31. (Amended) A method for the production of an oligomer [according to claim 1] comprising the steps of:

oligomerizing a unit, wherein each unit comprises at least one peptidic domain capable of oligomerizing and at least one domain capable of binding to an acceptor, wherein the peptidic domain is not an antibody or a functional antibody fragment from a constant region of an antibody;
and,

isolating the oligomer produced therefrom.

Kindly add the following claim:

33. (New). The oligomer of claim 6 wherein the spacer comprises at least one hinge region.


REMARKS

Claims 1, 6, 14-26 and 31 have been amended. Claim 33 has been add and incorporates material from claim 6 as originally filed.

A Substitute Sequence Listing has been provided along with a Computer Readable Form of the Sequence Listing. The under signed hereby states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR 1.821 including 1.821(c) and 1.821(e) are identical. No new matter has been added by any of these amendments. Favorable consideration of this application is respectfully requested.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6938


Myra H. McCormack, Ph.D.
Attorney for Applicants
Reg. No. 36,602

Date: April 28, 1999